tert-Butyl 5-chloroisoindoline-2-carboxylate

Catalog No.: 
ACZPNS386
CAS No.: 
871723-38-5
Molecular Formula: 
C13H16ClNO2
Molecular Weight: 
253.73
tert-Butyl 5-chloroisoindoline-2-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g97%$69.00In stockInquiry
25g97%$342.00InquiryInquiry
100g97%$1354.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 5-chloroisoindoline-2-carboxylate
IUPAC Nametert-butyl 5-chloroisoindoline-2-carboxylate
MDL No.MFCD16620845
Molecular FormulaC13H16ClNO2
Molecular Weight253.73
SMILESO=C(N1CC2=C(C=C(Cl)C=C2)C1)OC(C)(C)C
InChI KeyJJFMSBCYYHKSBX-UHFFFAOYSA-N
Synonymtert-butyl-5-chloroisoindoline-2-carboxylate;2H-Isoindole-2-carboxylic acid, 5-chloro-1,3-dihydro-, 1,1-dimethylethylester;1H,3H-Naphtho[1,8-cd]pyran-1,3-dione,6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-5-yl)-
CAS No.871723-38-5
PubChem CID57985348

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H317
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACZPNS386 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFOHV508 route compound structure diagram
    ACFOHV508912999-79-2In Stock
  4. Then
  5. ACZPNS386 route product structure diagram
    ACZPNS386871723-38-5In Stock
Inquiry

2. ACZPNS386 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZPNS386 route product structure diagram
    ACZPNS386871723-38-5In Stock
Inquiry

3. ACZPNS386 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZPNS386 route product structure diagram
    ACZPNS386871723-38-5In Stock
Inquiry

Comments (0)